Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
